Literature DB >> 21121856

Paroxysmal nocturnal hemoglobinuria--hemolysis before and after eculizumab.

Antonio M Risitano, Rosario Notaro, Lucio Luzzatto, Anita Hill, Richard Kelly, Peter Hillmen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21121856     DOI： 10.1056/NEJMc1010351

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  18 in total

Review 1.  From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage.

Authors:  Dimitrios C Mastellos; Edimara S Reis; Despina Yancopoulou; George Hajishengallis; Daniel Ricklin; John D Lambris
Journal:  Immunobiology       Date:  2016-06-16       Impact factor: 3.144

Review 2.  Molecules Great and Small: The Complement System.

Authors:  Douglas R Mathern; Peter S Heeger
Journal:  Clin J Am Soc Nephrol       Date:  2015-01-07       Impact factor: 8.237

Review 3.  Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria.

Authors:  Charles J Parker
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 4.  Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.

Authors:  Dimitrios C Mastellos; Despina Yancopoulou; Petros Kokkinos; Markus Huber-Lang; George Hajishengallis; Ali R Biglarnia; Florea Lupu; Bo Nilsson; Antonio M Risitano; Daniel Ricklin; John D Lambris
Journal:  Eur J Clin Invest       Date:  2015-03-09       Impact factor: 4.686

Review 5.  Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

Authors:  Dimitrios C Mastellos; Edimara S Reis; Despina Yancopoulou; Antonio M Risitano; John D Lambris
Journal:  Semin Hematol       Date:  2018-02-14       Impact factor: 3.851

6.  Complement blockade with a C1 esterase inhibitor in paroxysmal nocturnal hemoglobinuria.

Authors:  Amy E DeZern; Marc Uknis; Xuan Yuan; Galina L Mukhina; Juan Varela; JoAnne Saye; Jeffrey Pu; Robert A Brodsky
Journal:  Exp Hematol       Date:  2014-07-14       Impact factor: 3.084

Review 7.  Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape.

Authors:  Dimitrios C Mastellos; Daniel Ricklin; Despina Yancopoulou; Antonio Risitano; John D Lambris
Journal:  Expert Rev Hematol       Date:  2014-09-02       Impact factor: 2.929

8.  Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria.

Authors:  Antonio M Risitano; Daniel Ricklin; Yijun Huang; Edimara S Reis; Hui Chen; Patrizia Ricci; Zhuoer Lin; Caterina Pascariello; Maddalena Raia; Michela Sica; Luigi Del Vecchio; Fabrizio Pane; Florea Lupu; Rosario Notaro; Ranillo R G Resuello; Robert A DeAngelis; John D Lambris
Journal:  Blood       Date:  2014-02-04       Impact factor: 22.113

9.  Antibody Inhibition of Properdin Prevents Complement-Mediated Intravascular and Extravascular Hemolysis.

Authors:  Damodar Gullipalli; Fengkui Zhang; Sayaka Sato; Yoshiyasu Ueda; Yuko Kimura; Madhu Golla; Takashi Miwa; Jianxiang Wang; Wen-Chao Song
Journal:  J Immunol       Date:  2018-06-13       Impact factor: 5.422

10.  Rational engineering of a minimized immune inhibitor with unique triple-targeting properties.

Authors:  Christoph Q Schmidt; Hongjun Bai; Zhuoer Lin; Antonio M Risitano; Paul N Barlow; Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2013-04-24       Impact factor: 5.426
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.